Edition:
United Kingdom

Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

259.84USD
21 Sep 2018
Change (% chg)

$2.06 (+0.80%)
Prev Close
$257.78
Open
$257.91
Day's High
$261.06
Day's Low
$255.79
Volume
323,408
Avg. Vol
110,163
52-wk High
$273.15
52-wk Low
$126.77

Chart for

About

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such... (more)

Overall

Beta: 0.94
Market Cap(Mil.): $2,981.39
Shares Outstanding(Mil.): 21.05
Dividend: --
Yield (%): --

Financials

  LGND.OQ Industry Sector
P/E (TTM): 374.89 85.68 32.76
EPS (TTM): 0.38 -- --
ROI: 2.31 1.79 14.61
ROE: 2.54 3.28 16.33

BRIEF-Ligand Prices Offering Of $650 Mln Of Convertible Senior Notes

* LIGAND PRICES OFFERING OF $650 MILLION OF CONVERTIBLE SENIOR NOTES

18 May 2018

BRIEF-Ligand Pharmaceuticals Announces Proposed Offering Of $650 Mln Of Convertible Senior Notes

* LIGAND ANNOUNCES PROPOSED OFFERING OF $650 MILLION OF CONVERTIBLE SENIOR NOTES

16 May 2018

BRIEF-Ligand Pharmaceuticals Entered Commercial Platform License Agreement, With KSQ Therapeutics

* LIGAND PHARMACEUTICALS - ON MAY 8, ENTERED COMMERCIAL PLATFORM LICENSE AGREEMENT, WITH KSQ THERAPEUTICS, INC - SEC FILING

10 May 2018

BRIEF-Ligand Reports Q1 Adjusted Earnings Per Share $1.55

* Q1 EARNINGS PER SHARE VIEW $1.15 -- THOMSON REUTERS I/B/E/S

08 May 2018

BRIEF-Ligand Pharma Says Co Sent Computershare, As Rights Agent Under Glucagon CVR Agreement

* LIGAND PHARMACEUTICALS SAYS HOLDERS OF GLUCAGON CVRS ENTITLED TO RECEIVE PRO RATA $3.8 MILLION Source text: (https://bit.ly/2JHfcOF) Further company coverage:

13 Apr 2018

BRIEF-Ligand Enters Into Agreement With venBio

* LIGAND ENTERS INTO AGREEMENT WITH VENBIO TO MAKE WORLDWIDE OMNIAB® PLATFORM LICENSE ACCESSIBLE TO PORTFOLIO COMPANIES Source text for Eikon: Further company coverage:

30 Mar 2018

Earnings vs. Estimates